Medicure Inc (TSE:MPH) has released an update.
Medicure Inc. has announced that its drug MC-1 received Fast Track designation from the U.S. FDA for the treatment of PNPO deficiency-related seizures, a rare neurometabolic disorder. This status could expedite the drug’s development and review process, given its potential to meet an unmet medical need. Additionally, Medicure may receive a priority review voucher from the FDA upon successful approval of a new drug application for MC-1.
For further insights into TSE:MPH stock, check out TipRanks’ Stock Analysis page.
